Form 4: Arrowhead Pharmaceuticals Director Sells Shares Under 10b5-1 Trading Plan

Adeoye Olukotun, a director at Arrowhead Pharmaceuticals, sold 2,850 shares of common stock at $20 per share on December 27, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On December 27, 2024, Adeoye Olukotun, a director of Arrowhead Pharmaceuticals, sold 2,850 shares of the company's common stock.
• The sale was executed at a price of $20 per share.
• The transaction was conducted under a 10b5-1 trading plan, which was previously established by Olukotun.
• Following the transaction, Olukotun directly owns 36,740 shares of Arrowhead Pharmaceuticals, which includes shares underlying Restricted Stock Units (RSUs) that are subject to vesting conditions.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged plan. There is no indication of positive or negative implications for the company.

Industry Context

Sales by company insiders are a common occurrence and are often scrutinized by investors. Sales under a 10b5-1 plan are generally viewed as less concerning because they are pre-arranged and not based on current insider information.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates